热门资讯> 正文
EyePoint因与铅资产相关的索赔而受到关注
2026-03-21 22:23
- EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that its rival eye drug developer made false claims regarding its lead candidate, Duravyu.
- According to the lawsuit filed in Middlesex County Superior Court in Massachusetts on Friday, EyePoint (EYPT) accused Ocular (OCUL) of spreading false or misleading information regarding the company and clinical findings of Duravyu.
- The intravitreal injection is currently undergoing late-stage development for ophthalmic conditions, including wet age-related macular degeneration (wet AMD), a condition targeted by Ocular’s (OCUL) lead asset, Axpaxli. Both treatments belong to a class of drugs known as tyrosine kinase inhibitors.
- The lawsuit seeks an injunction to block the defendant from continuing with the alleged dissemination of false claims, retraction of the statements, and recovery of financial damages.
More on EyePoint Pharmaceuticals, Ocular Therapeutix
- EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check
- EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
- Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula Society - Slideshow
- EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance
- Ocular drops after late-stage trial data for wet AMD therapy
推荐文章
美股机会日报 | 特朗普再放豪言！正与伊朗谈判，并收到伊方“大礼”；特斯拉机器人再迎新进展！马斯克称有望明年实现量产
一图看懂 | 单季盈利承压！拼多多Q4营收1239亿元同比增12%，调后净利却下跌12%；高管称“力争三年再造一个拼多多”
财报前瞻 | 美团Q4财报明日放榜！大摩、高盛逆势力挺股价，当前美团已严重超跌？
中东战火中金价狂泻11%！创43年最惨周跌，避险逻辑崩塌还是黄金坑？
美股机会日报 | 中东硝烟将散？以官员称美方4月9日结束对伊战争！海力士拟筹资百亿赴美上市，豪掷80亿美元锁定阿斯麦光刻机！
一图看懂 | 连续5个季度破千亿！小米Q4营收1169亿创历史新高；净利大增43.8%至63亿元
无论美伊谈判真假！华尔街已从特朗普引发的五分钟狂飙获得明确信号？
麦格理：紧张局势缓和后布伦特原油底部在每桶85至90美元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
